| Bioactivity | PBI-6DNJ is an orally active and potent multivalent glycosidase inhibitor. PBI-6DNJ exhibits good inhibition activity against α-glucosidase from mice, with a Ki of 0.14 μM. PBI-6DNJ exhibits good hypoglycemic activity. PBI-6DNJ can be used for type 2 diabetes research[1]. |
| Target | Ki: 0.02 ± 0.002 μM (α-glucosidase from rice), 0.08 ± 0.03 μM (α-mannosidase from jack bean), 0.14 ± 0.007 μM (α-glucosidase from mice), 18.88 ± 0.30 μM (α-glucosidase from aspergilcus niger) |
| In Vivo | PBI-6DNJ (0-2 mg/kg, Orally, once) reduces postprandial blood glucose (PBG) levels[1]. PBI-6DNJ (2.0 mg/kg, Orally, daily for 7 day) has good biocompatibility and no damage to mice[1]. Animal Model: |
| Name | PBI-6DNJ |
| Formula | C120H146N26O36 |
| Molar Mass | 2528.60 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Jian-XingYang, et al. Multivalent glucosidase inhibitors based on perylene bisimide and iminosugar conjugates. European Journal of Medicinal Chemistry. 2022 November 5, 241(3):114621. |